Eledon Pharmaceuticals
ELDN
20 hedge funds and large institutions have $5.93M invested in Eledon Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
25% more funds holding
Funds holding: 16 → 20 (+4)
9.44% more ownership
Funds ownership: 35.82% → 45.26% (+9.4%)
56% less capital invested
Capital invested by funds: $13.6M → $5.93M (-$7.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.01M |
| 2 |
O
OrbiMed
New York
|
+$1.57M |
| 3 |
6CM
683 Capital Management
New York
|
+$785K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$552K |
| 5 |
Renaissance Technologies
New York
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$44K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.75K |
| 4 |
Morgan Stanley
New York
|
-$481 |
ELDN Hedge Fund Activity: Q2 2019 in Review
20 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2019, worth a combined $5.93M — down 56% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ELDN positions and 3 closed out — a net gain of 4 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $2.01M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $44K sold.
- 20 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2019, up from 16 in Q1 2019.
- Funds reported $5.93M of Eledon Pharmaceuticals stock for Q2 2019, down 56% quarter-over-quarter.
- 7 funds opened new Eledon Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +4 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2019 was BVF Inc, an estimated $2.01M added.
- The largest Eledon Pharmaceuticals seller in Q2 2019 was Raymond James & Associates, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2019.